UNSPSC 85815028: Introduction of monoclonal antibody into products of conception, via natural or artificial opening

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of monoclonal antibody into products of conception, via natural or artificial opening. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0E70M

UNSPSC 85815028 Introduction of monoclonal antibody into products of conception, via natural or artificial opening is a Commodity code with minimal relevance to actual state and local procurement activity. The code's clinical description—a narrowly specified obstetric or gynecological procedure involving monoclonal antibody administration—does not align with the recent opportunities posted under this identifier. The posted opportunities span virtual urgent care services, occupational health examinations, behavioral health programming, EMS revenue billing, orthotic equipment, cancer screening, radiology services, and nursing home operations; none involve monoclonal antibody infusion for pregnancy-related indications. State and local procurement offices appear to have tagged these opportunities with this code in error, reflecting systematic miscoding rather than actual market demand for the procedure itself.

The issuing bodies represent a broad mix of health systems, counties, and special-purpose districts across multiple states: Inland Empire Health Plan and San Mateo Medical Center in California; DeKalb County, Georgia; Nevada Health Authority; Boulder County, Colorado; City of Ocala, Florida; Cobb County and Seminole County, Florida; Brevard County, Florida; Santa Clara County, California; Phoenix, Arizona; Fairfax County, Virginia; and additional jurisdictions. Geographic distribution spans California, Georgia, Nevada, Colorado, Florida, Texas, Kansas, New York, and other states. Because the code itself does not describe what state and local government actually buys under this taxonomy entry, and the posted opportunities show no purchase intent for monoclonal antibody procedures, this code should be deprioritized or excluded from active pursuit portfolios absent direct evidence of procedural service procurements.